Why Is Mangalam Drugs and Organics Share Price Falling Key Reasons 2026

The Mangalam Drugs and Organics share price falling trend has become a key investor concern in 2026. With Mangalam Drugs and Organics share price falling approximately 3 percent from its 52 week high of Rs 31 to current levels near Rs 30, investors are asking whether this correction represents a buying opportunity or signals deeper structural challenges. Mangalam Drugs and Organics (NSE: MANGALAMDRG), listed in the Pharmaceutical Bulk Drugs and APIs space, has witnessed sustained selling pressure through FY26. Understanding the Mangalam Drugs and Organics share price falling narrative requires careful analysis of both company-specific headwinds and the broader macro forces at work in 2026.

Click Here Get Free Investment Predictions

About Mangalam Drugs and Organics

Manufacturer of pharmaceutical bulk drugs and organic chemical intermediates. BSE-listed. Circuit range Rs 28 to Rs 31. Revenue Rs 200 crore. CMP Rs 30. The stock is trading at approximately Rs 30, down approximately 3 percent from its 52 week high of Rs 31. The 52 week low stands at Rs 28. The Mangalam Drugs and Organics share price falling trend reflects both sector headwinds and company-specific pressures that investors need to evaluate carefully.

Parameter	Value
NSE Ticker	MANGALAMDRG
Sector	Pharmaceutical Bulk Drugs and APIs
CMP (2026)	Rs 30
52 Week High	Rs 31
52 Week Low	Rs 28
Decline from 52W High	Approximately 3 percent
Market Cap	Rs 300 crore (approx)
Trailing P/E	15x

Why Is Mangalam Drugs and Organics Share Price Falling: Key Reasons

Use the Univest Screener to check live fundamentals of Mangalam Drugs and Organics and compare with peers.

1. FII Selling and Broad Market Correction

The dominant external driver behind the Mangalam Drugs and Organics share price falling is the sustained FII selling wave that swept Indian equities through FY26. The US reciprocal tariff announcement imposing a 26 percent levy on Indian goods triggered a broad risk-off selloff that saw FIIs pull significant capital from Indian equity markets. Mangalam Drugs and Organics fell alongside the broader correction. The Mangalam Drugs and Organics share price falling by 3 percent from its peak reflects the combination of macro-level FII selling and company-specific headwinds operating simultaneously in 2026.

2. Sector-Specific Headwinds in Pharmaceutical Bulk Drugs and APIs

Beyond the broad market decline, the Pharmaceutical Bulk Drugs and APIs sector has faced its own challenges in FY26. Analyst earnings estimates for the Pharmaceutical Bulk Drugs and APIs space have been revised downward as input costs, competitive pricing pressures and demand moderation weighed on sector outlook. When sector-level earnings expectations decline simultaneously, institutional investors reduce overall sector exposure, leading to uniform price declines across the peer group. The Mangalam Drugs and Organics share price falling trend is in part a function of this broader sector de-rating that continued through 2026.

3. Earnings Growth Deceleration and Margin Compression

A significant company-specific driver behind the Mangalam Drugs and Organics share price falling is the deceleration in earnings growth relative to the elevated expectations priced in at its 52 week high of Rs 31. Revenue and profitability have come under pressure from input cost inflation, competitive pricing constraints and higher operating expenditure. The market is now recalibrating to a more moderate earnings trajectory, which has become a core driver of the Mangalam Drugs and Organics share price falling below prior analyst targets.

4. Valuation De-Rating from Peak Multiples

At its 52 week high of Rs 31, Mangalam Drugs and Organics was trading at valuation multiples above its historical average. As actual results came in below peak expectations and sector sentiment turned cautious, the market applied lower multiples to Mangalam Drugs and Organics earnings. This valuation de-rating from Rs 31 to the current Rs 30 explains a significant portion of the 3 percent decline in the Mangalam Drugs and Organics share price falling phase.

5. Small and Mid Cap Liquidity Squeeze

With a market capitalisation of approximately Rs 300 crore, Mangalam Drugs and Organics is exposed to the liquidity dynamics of the small and mid cap segment, which experienced a sharp liquidity squeeze in FY25-26. When domestic mutual funds face redemption pressure and retail investors turn risk-averse, smaller companies bear disproportionate selling pressure, amplifying the Mangalam Drugs and Organics share price falling trend beyond what fundamentals would suggest.

6. Global Macroeconomic Uncertainty

India’s equity market in FY26 faced an unusually concentrated set of macro headwinds including global tariff wars, crude oil price volatility, currency pressure and concerns about the pace of domestic earnings recovery. The Mangalam Drugs and Organics share price falling trend has been reinforced by this macro overhang that keeps institutional buyers cautious even when individual company fundamentals do not fully justify the magnitude of the decline.

Financial Performance Analysis of Mangalam Drugs and Organics

The key financial metrics driving the Mangalam Drugs and Organics share price falling narrative are visible in both recent quarterly trends and valuation de-rating. The stock has fallen 3 percent from its 52 week high of Rs 31 to the current Rs 30. The market cap has contracted to approximately Rs 300 crore. Investors tracking the Mangalam Drugs and Organics share price falling should monitor the upcoming results and management commentary on margin and revenue recovery.

Key Metric	Current Level	52 Week Peak	Trend
Share Price	Rs 30	Rs 31	Down 3 percent
Market Cap (Rs Cr)	Rs 300 crore	Higher at 52W peak	Compressed with price
Trailing P/E	15x	Higher at 52W high	Multiple compressed
52 Week Range	Rs 28 to Rs 31

Technical Signals What the Charts Are Saying

On the technical charts, the Mangalam Drugs and Organics share price falling pattern is confirmed by the stock trading below its 50 day, 100 day, and 200 day simple moving averages, all of which are sloping downward. Since its 52 week high of Rs 31, Mangalam Drugs and Organics has formed a pattern of lower highs and lower lows. Key support for the Mangalam Drugs and Organics share price falling trend is at the 52 week low of Rs 28. Overhead resistance is at the Rs 31 zone where investors who bought near the peak create selling pressure on recovery attempts. Download the Univest iOS App or Univest Android App to track Mangalam Drugs and Organics live price and get daily expert stock picks.

Can Mangalam Drugs and Organics Share Price Recover

Despite the headwinds currently driving the Mangalam Drugs and Organics share price falling, genuine recovery catalysts exist for long-term investors. First, any positive inflection in the Pharmaceutical Bulk Drugs and APIs sector driven by improved macro conditions or policy support could trigger a sharp re-rating for Mangalam Drugs and Organics. Second, a quarterly earnings result that beats the now-reduced analyst expectations could catalyse a short-covering rally from oversold levels. Third, a broad recovery in Indian small and mid cap market sentiment as FII flows normalise would lift Mangalam Drugs and Organics along with the broader peer group.

The contrarian view is that at Rs 30, a significant portion of the bad news driving the Mangalam Drugs and Organics share price falling is already priced in. The stock is down 3 percent from its peak and the valuation has compressed meaningfully, creating a potentially attractive entry point for patient investors with a 2 to 3 year horizon.

Conclusion

The Mangalam Drugs and Organics share price falling by approximately 3 percent from its 52 week high of Rs 31 to the current Rs 30 reflects broad market headwinds, FII selling, earnings deceleration and valuation de-rating in the Pharmaceutical Bulk Drugs and APIs sector. The Mangalam Drugs and Organics share price falling trend will require a clear reversal in quarterly financial momentum and improved macro sentiment to arrest sustainably. Investors monitoring the Mangalam Drugs and Organics share price falling should closely watch upcoming results, management commentary on growth and margin recovery, and shifts in FII ownership. For real-time tracking, visit Univest.

Disclaimer Note: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Data sourced from publicly available open sources. SEBI Registration No. INH000013776.

Frequently Asked Questions

Why is Mangalam Drugs and Organics share price falling in 2026?

Ans. The Mangalam Drugs and Organics share price falling in 2026 is driven by FII selling triggered by the US tariff announcement, sector headwinds in the Pharmaceutical Bulk Drugs and APIs space, earnings deceleration, and valuation de-rating from peak multiples. The decline is approximately 3% from the 52 week high of Rs 31 to Rs 30.

What is the 52 week high and low of Mangalam Drugs and Organics?

Ans. The 52 week high of Mangalam Drugs and Organics is Rs 31 and the 52 week low is Rs 28. The current price of approximately Rs 30 represents a decline of about 3% from the 52 week high.

Should I buy Mangalam Drugs and Organics shares at current levels?

Ans. Whether to buy Mangalam Drugs and Organics at Rs 30 depends on your investment horizon and risk appetite. The stock has fallen 3% from its peak, which may improve the risk-reward for long-term investors. Always consult a SEBI registered financial advisor before any investment decision.

What are the recovery triggers for Mangalam Drugs and Organics?

Ans. Key recovery catalysts for Mangalam Drugs and Organics include quarterly earnings beating reduced analyst expectations, reversal of FII selling as global macro improves, positive sector re-rating in the Pharmaceutical Bulk Drugs and APIs space, and a broader Indian mid and small cap market recovery.

What are the key downside risks to Mangalam Drugs and Organics stock?

Ans. Key risks include continued earnings estimate downgrades, further FII selling, unexpected regulatory or competitive developments in the Pharmaceutical Bulk Drugs and APIs sector, and a deeper correction in the broader Indian equity market testing the 52 week low of Rs 28.

What is the market cap of Mangalam Drugs and Organics?

Ans. The current market capitalisation of Mangalam Drugs and Organics is approximately Rs 300 crore based on the CMP of Rs 30. The market cap has compressed from its peak as the Mangalam Drugs and Organics share price falling trend has persisted through 2026.